Ejso最新文献

筛选
英文 中文
Balance between chronological aging and functional reserve: Clinical value of age/mFI-5 ratio in prognostic prediction for elderly brain tumor surgery. 年龄/mFI-5比值在老年脑肿瘤手术预后预测中的临床价值
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-12 DOI: 10.1016/j.ejso.2026.112366
Xiaobo Ye, Fuyu Tian, Hui Li, Xi Zhang, Pengyu Huang, Yicong Dong, Yutao Ren, Huanfa Li, Yong Liu, Changwang Du, Hao Wu, Hua Zhang, Qiang Meng
{"title":"Balance between chronological aging and functional reserve: Clinical value of age/mFI-5 ratio in prognostic prediction for elderly brain tumor surgery.","authors":"Xiaobo Ye, Fuyu Tian, Hui Li, Xi Zhang, Pengyu Huang, Yicong Dong, Yutao Ren, Huanfa Li, Yong Liu, Changwang Du, Hao Wu, Hua Zhang, Qiang Meng","doi":"10.1016/j.ejso.2026.112366","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112366","url":null,"abstract":"<p><strong>Background: </strong>Both advanced age and frailty influence postoperative outcomes in elderly brain tumor patients, but their interaction remains underexplored. We introduced the age/mFI-5 ratio (AMR), a novel composite indicator, and assessed its predictive value for adverse outcomes after brain tumor surgery.</p><p><strong>Methods: </strong>This retrospective cohort study included elderly patients who underwent brain tumor resection at the First Affiliated Hospital of Xi'an Jiaotong University (January 2023-January 2024). The optimal AMR cutoff was determined by the maximum Youden index, dividing patients into low- and high-AMR groups. Baseline characteristics and clinical outcomes were compared. Univariate and multivariable logistic regressions identified independent predictors of adverse prognosis, and ROC analysis compared AMR with age and mFI-5 alone.</p><p><strong>Results: </strong>Among 160 patients, the optimal AMR cutoff was 50. The low-AMR group had significantly higher rates of all adverse outcomes (all P < 0.05). Low AMR independently predicted adverse prognosis (OR = 16.17, 95% CI 6.27-41.72, P < 0.001) and was strongly associated with reoperation (adjusted OR = 23.27), complications (8.28), eLOS (10.95), and unfavorable discharge (34.52) (all P < 0.001). AMR showed superior AUC (0.846) versus age (0.561) and mFI-5 (0.795).</p><p><strong>Conclusions: </strong>AMR with a cutoff of 50 is a simple, readily available, and independent predictor of adverse postoperative outcomes in elderly brain tumor surgery patients. It outperforms age or frailty alone by capturing their synergistic effect, and routine calculation could potentially aid preoperative risk stratification and guide individualized perioperative care. However, external validation in an independent cohort is required before AMR can be recommended for routine clinical use.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112366"},"PeriodicalIF":3.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A peritoneal cancer index above 14 is associated with incomplete cytoreduction in cytoreductive surgery with HIPEC for high-grade serous ovarian cancer. 在高级别浆液性卵巢癌的HIPEC减胞手术中,腹膜癌指数高于14与细胞不完全减少相关。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-10 DOI: 10.1016/j.ejso.2026.112367
Andrea Bertolucci, Erion Rreka, Lorenzo Piccini, Alfonso Greco, Barbara Musco, Mauro Ferrari, Niccolò Ramacciotti, Pinuccia Faviana, Piero Vincenzo Lippolis
{"title":"A peritoneal cancer index above 14 is associated with incomplete cytoreduction in cytoreductive surgery with HIPEC for high-grade serous ovarian cancer.","authors":"Andrea Bertolucci, Erion Rreka, Lorenzo Piccini, Alfonso Greco, Barbara Musco, Mauro Ferrari, Niccolò Ramacciotti, Pinuccia Faviana, Piero Vincenzo Lippolis","doi":"10.1016/j.ejso.2026.112367","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112367","url":null,"abstract":"<p><strong>Introduction: </strong>The peritoneal cancer index (PCI) is used both to predict resectability and to estimate prognosis in ovarian cancer. We aimed to identify the PCI threshold predicting incomplete cytoreduction at cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and to describe its relation to survival.</p><p><strong>Materials and methods: </strong>Retrospective single-centre cohort of 112 consecutive patients with high-grade serous tubo-ovarian carcinoma treated with CRS and cisplatin HIPEC (2016-2023): 87 at interval CRS after neoadjuvant chemotherapy (primary population) and 25 at secondary CRS. PCI was related to residual disease (CC-1/2) with bootstrap-corrected ROC analysis and Firth regression, and to survival with Cox models and restricted mean survival time (RMST).</p><p><strong>Results: </strong>At interval CRS, residual disease occurred in 10/26 patients (38%) with PCI > 14 and in 2/61 (3%) with PCI ≤ 14 (AUC 0.82; optimism-corrected 0.82). PCI > 14 was associated with shorter overall survival (median 27 vs 57 months; HR 2.15 (1.11-4.16)) and progression-free survival (RMST difference at 36 months -7.1 months, 95% CI -12.9 to -1.2). Small-bowel or mesenteric involvement, abstracted blind from operative reports, did not predict residual disease independently of PCI > 14. With complete cytoreduction (n = 75), each PCI point was associated with shorter overall survival (HR 1.07 (1.01-1.12)).</p><p><strong>Conclusion: </strong>At CRS-HIPEC for high-grade serous ovarian cancer, PCI > 14 identifies patients in whom complete cytoreduction is uncertain, reflecting total disease burden rather than small-bowel involvement alone. PCI retained prognostic information after complete cytoreduction. The threshold should guide surgical planning and counselling rather than exclusion, and requires external validation.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112367"},"PeriodicalIF":3.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zone-specific lymph node metastasis prediction model in clinical stage I-II non-small cell lung cancer: a supplementary analysis of JCOG1413. 临床I-II期非小细胞肺癌区域特异性淋巴结转移预测模型:JCOG1413的补充分析
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-10 DOI: 10.1016/j.ejso.2026.112363
Mitsuhiro Isaka, Tomoyuki Hishida, Hisashi Saji, Masashi Wakabayashi, Yasuhisa Ohde, Yasuhiro Tsutani, Makoto Endo, Takahiro Mimae, Tomohiro Miyoshi, Tetsuya Isaka, Aritoshi Hattori, Hiroshige Yoshioka, Ryu Nakajima, Masaya Yotsukura, Tomohiro Maniwa, Kazuo Nakagawa, Noriko Mitome, Yuta Sekino, Haruhiko Fukuda, Keiju Aokage, Shun-Ichi Watanabe, Morihito Okada
{"title":"Zone-specific lymph node metastasis prediction model in clinical stage I-II non-small cell lung cancer: a supplementary analysis of JCOG1413.","authors":"Mitsuhiro Isaka, Tomoyuki Hishida, Hisashi Saji, Masashi Wakabayashi, Yasuhisa Ohde, Yasuhiro Tsutani, Makoto Endo, Takahiro Mimae, Tomohiro Miyoshi, Tetsuya Isaka, Aritoshi Hattori, Hiroshige Yoshioka, Ryu Nakajima, Masaya Yotsukura, Tomohiro Maniwa, Kazuo Nakagawa, Noriko Mitome, Yuta Sekino, Haruhiko Fukuda, Keiju Aokage, Shun-Ichi Watanabe, Morihito Okada","doi":"10.1016/j.ejso.2026.112363","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112363","url":null,"abstract":"<p><strong>Background: </strong>The optimal extent of lymph node dissection in early-stage non-small cell lung cancer remains unclear. We aimed to develop zone-specific lymph node metastasis prediction models for clinical stage I-II non-small cell lung cancer using data from the Japan Clinical Oncology Group (JCOG) 1413, a randomized phase III trial comparing lobe-specific and systematic lymph node dissection.</p><p><strong>Methods: </strong>The analysis included 1699 eligible cases out of 1711 patients from 44 institutions in JCOG1413. Leave-one-out cross-validation was used to evaluate the prediction algorithm, and multivariable logistic regression identified independent predictors of metastasis for constructing nomograms. Model performance was assessed using receiver operating characteristic curves with concordance statistics and calibration curves with calibration slope.</p><p><strong>Results: </strong>We developed models for four zones: upper (including the aortopulmonary zone) (n = 1416), subcarinal (n = 1170), hilar (n = 1662), and peripheral (n = 1662). Common independent predictors included histology, maximum standardized uptake on positron emission tomography, and, particularly for mediastinal zones, primary tumor lobe location. The subcarinal zone showed the best performance, with a concordance statistic of 0.7902 and a calibration slope of 1.0762. Across all zones, calibration slopes remained close to 1.0, and negative predictive values ranged from 96.6% to 99.4%.</p><p><strong>Conclusions: </strong>Zone-specific prediction models demonstrated moderate discrimination and well-calibrated estimates of lymph-node metastasis risk, with the highest performance observed in the subcarinal zone. These models could support risk stratification and facilitate individualized intraoperative nodal assessment to inform clinical decision-making.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112363"},"PeriodicalIF":3.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of patient delay on laryngeal cancer stage at diagnosis - A systematic review. 患者延迟对喉癌诊断分期的影响-一项系统综述。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-06 DOI: 10.1016/j.ejso.2026.112358
Maya Ben Avi Borreda, Rania Faris, Ohad Ronen
{"title":"The effect of patient delay on laryngeal cancer stage at diagnosis - A systematic review.","authors":"Maya Ben Avi Borreda, Rania Faris, Ohad Ronen","doi":"10.1016/j.ejso.2026.112358","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112358","url":null,"abstract":"<p><strong>Background: </strong>Patient delay before first medical consultation is common in head and neck malignancies, but its association with stage at diagnosis in laryngeal cancer remains unclear. Our objective was to assess whether patient delay is associated with stage at diagnosis in laryngeal cancer.</p><p><strong>Methods: </strong>A systematic literature review was performed in PubMed and Embase (October 2025). English-language human studies were included if they reported patient delay and stage at diagnosis in laryngeal cancer or head and neck cancer cohorts with extractable laryngeal data. The overall certainty of evidence for the primary outcome was evaluated.</p><p><strong>Results: </strong>Twenty-six studies were included (5979 patients; 2150 laryngeal cancer). Stage-stratified patient delay data specific to laryngeal cancer were reported in only one larynx-specific study, precluding pooled larynx-only comparisons. A supplementary descriptive summary of six studies (631 patients), comprising one larynx-only study and five mixed HNC studies, showed a weighted mean patient delay of 66.7 days for early-stage disease and 46.5 days for late-stage disease; these estimates are not larynx-specific. The overall certainty of evidence was low, due to high between-study heterogeneity, the indirectness of evidence from mixed head and neck cancer cohorts, and small cohort numbers with no calculable CIs.</p><p><strong>Conclusion: </strong>Current evidence does not show a consistent pattern in which longer patient delay reliably predicts advanced stage at diagnosis in laryngeal cancer. Standardized delay definitions and subsite-stratified reporting are needed. Given the very low certainty of current evidence, larynx-specific prospective studies with standardized delay definitions, and explicit subsite stratification are required before definitive conclusions can be drawn.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112358"},"PeriodicalIF":3.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-dependent prognostic value of preoperative CA19-9 after resection of hilar-type intrahepatic cholangiocarcinoma. 肝门型肝内胆管癌切除术后术前CA19-9的时间依赖性预后价值。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-06 DOI: 10.1016/j.ejso.2026.112360
Di Zeng, Zhimeng Cheng, Jiong Lu
{"title":"Time-dependent prognostic value of preoperative CA19-9 after resection of hilar-type intrahepatic cholangiocarcinoma.","authors":"Di Zeng, Zhimeng Cheng, Jiong Lu","doi":"10.1016/j.ejso.2026.112360","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112360","url":null,"abstract":"<p><strong>Background: </strong>Preoperative CA19-9 is an established prognostic marker after cholangiocarcinoma resection. We examined whether its association with recurrence differed before and after an event-free first postoperative year.</p><p><strong>Methods: </strong>This retrospective single-centre cohort included 253 patients undergoing curative-intent resection for hilar-type intrahepatic cholangiocarcinoma during 2003-2023. The original 500 U/mL comparison was evaluated using competing-risk estimation, cause-specific Cox models, a coefficient change at day 365, and landmark analyses. Exploratory analyses examined calendar-era heterogeneity and continuous CA19-9 below the assay ceiling.</p><p><strong>Results: </strong>There were 173 recurrences and 144 deaths. CA19-9 ≥500 U/mL was not clearly associated with first-year recurrence (adjusted HR 1.06 (95% CI 0.72-1.58)). Among 125 patients alive and recurrence-free at day 365, its association with subsequent recurrence was stronger (HR 3.43 (95% CI 2.01-5.84)); the time interaction was significant (P = 0.001). However, the association varied by calendar year (interaction P = 0.003) and was not clearly reproduced in the 2017-2023 subgroup (within-era HR 1.20 (95% CI 0.46-3.12)). Below 1000 U/mL, continuous CA19-9 showed no clear post-landmark association (HR per doubling of CA19-9 + 1, 0.99 (95% CI 0.82-1.19)).</p><p><strong>Conclusion: </strong>The full cohort showed a stronger association between high baseline CA19-9 and recurrence after an event-free first year. Era heterogeneity, threshold dependence, unavailable postoperative biomarkers and incomplete treatment timing limit interpretation. These exploratory findings do not establish a treatment or surveillance strategy.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112360"},"PeriodicalIF":3.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of transvaginal ultrasound with endorectal micro-enema for the detection of rectosigmoid anastomotic leakage after cytoreductive surgery for ovarian cancer: preliminary experience from an ambispective single-center study. 经阴道超声联合直肠内微灌肠检测卵巢癌细胞减少术后直肠乙状结肠吻合口漏的可行性:双镜单中心研究的初步经验。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-05 DOI: 10.1016/j.ejso.2026.112356
Floriana Mascilini, Marianna Ciancia, Francesca Moro, Lorena Quagliozzi, Federica Pozzati, Maria Teresa Giudice, Elena Teodorico, Giulia Zinicola, Francesca Ciccarone, Chiara Caricato, Francesco Santullo, Virginia Vargiu, Antonia Carla Testa, Anna Fagotti
{"title":"Feasibility of transvaginal ultrasound with endorectal micro-enema for the detection of rectosigmoid anastomotic leakage after cytoreductive surgery for ovarian cancer: preliminary experience from an ambispective single-center study.","authors":"Floriana Mascilini, Marianna Ciancia, Francesca Moro, Lorena Quagliozzi, Federica Pozzati, Maria Teresa Giudice, Elena Teodorico, Giulia Zinicola, Francesca Ciccarone, Chiara Caricato, Francesco Santullo, Virginia Vargiu, Antonia Carla Testa, Anna Fagotti","doi":"10.1016/j.ejso.2026.112356","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112356","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the feasibility of transvaginal ultrasound with endorectal micro-enema for post-operative assessment of rectosigmoid anastomosis leakage in patients undergoing cytoreductive surgery for ovarian cancer.</p><p><strong>Methods: </strong>This ambispective single-center study included patients with ovarian cancer who underwent primary or interval debulking surgery, or surgery for recurrent disease, with bowel resection and rectosigmoid anastomosis. Transvaginal ultrasound-guided assessment with endorectal saline instillation was performed between postoperative day 5 and 7. Contrast-enhanced CT was used as the reference standard in cases suspicious for anastomotic leakage.</p><p><strong>Results: </strong>Between January 2024 and December 2025, 67 patients were assessed for participation in the study. The procedure was attempted in 49 patients and successfully completed in 42 (85.7%). Procedural difficulty was rated as easy in 32/42 (76.2%) cases, mildly difficult in 8/42 (19.0%) and moderately difficult in 2/42 (4.8%). Image quality was rated as good or excellent in 34/42 (81.0%) examinations and adequate in 8/42 (19.0%). The pain intensity during the procedure was rated as mild in 35/42 (83.3%) patients and moderate in 7/42 (16.7%), no patient reported severe pain. No procedure-related complications occurred. Ultrasound findings were negative in 40/42 cases, indeterminate in 1, and positive in 1 case of anastomotic leakage, which was confirmed by CT and managed surgically.</p><p><strong>Conclusion: </strong>Transvaginal ultrasound with endorectal micro-enema appeared to be a feasible, and well-tolerated bedside technique for postoperative assessment of rectosigmoid anastomosis after cytoreductive surgery for ovarian cancer, with no procedure-related complications observed in this preliminary experience. These findings support further multicenter studies to validate its diagnostic performance and clinical utility.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112356"},"PeriodicalIF":3.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time from diagnosis to initial treatment and survival in non-metastatic oesophago-gastric cancer: a systematic review. 非转移性食管胃癌从诊断到初始治疗的时间和生存率:一项系统综述。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-05 DOI: 10.1016/j.ejso.2026.112362
O O'Connor, S Epton, A McDonell, K Darley, T Crosby, B Thomas, J Gossage, N Trudgill, D A Cromwell, M H Park
{"title":"Time from diagnosis to initial treatment and survival in non-metastatic oesophago-gastric cancer: a systematic review.","authors":"O O'Connor, S Epton, A McDonell, K Darley, T Crosby, B Thomas, J Gossage, N Trudgill, D A Cromwell, M H Park","doi":"10.1016/j.ejso.2026.112362","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112362","url":null,"abstract":"<p><strong>Background: </strong>Timely initiation of treatment is a key principle in cancer care but can be difficult for oesophago-gastric (OG) cancer services due to the complex staging pathway. This study reviewed the evidence on the impact of the diagnostic-to-treatment interval (DTI) on survival for OG cancer patients.</p><p><strong>Methods: </strong>A systematic review of observational studies examining DTI and overall survival (OS) in oesophageal and gastric cancer was undertaken. Given substantial heterogeneity in interval definitions, exposure modelling, and analytical approaches, meta-analysis was not considered methodologically appropriate; therefore, a structured narrative synthesis was performed, focusing on threshold effects across the DTI distribution.</p><p><strong>Results: </strong>Twenty studies were identified (12 evaluated gastric cancer; 8 oesophageal). Sample sizes ranged from 103 to 12,764 patients. DTIs of approximately 30-90 days were not consistently associated with worse overall survival. Longer intervals, typically beyond 90 days, were more frequently associated with poorer outcomes, although findings were inconsistent. All studies were at moderate or serious risk of bias, and selection of patients who ultimately received treatment may have attenuated associations at longer intervals. Poorer outcomes at shorter DTIs were also observed, consistent with clinical prioritisation and the 'waiting-time paradox'.</p><p><strong>Conclusion: </strong>The current evidence base contains heterogeneous results that are susceptible to bias. Observational studies did not demonstrate a consistent association between DTIs of approximately 30-90 days and worse overall survival. Some studies suggested poorer outcomes beyond approximately 90 days, although findings were inconsistent, and the current evidence is insufficient to define a clinically safe DTI threshold.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112362"},"PeriodicalIF":3.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TNT in older patients: How fit do you have to be? 老年患者的TNT:你需要多健康?
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-05 DOI: 10.1016/j.ejso.2026.112353
Timothy Kravchenko, Pasithorn A Suwanabol, Nicole M Saur, Terrah J Paul Olson
{"title":"TNT in older patients: How fit do you have to be?","authors":"Timothy Kravchenko, Pasithorn A Suwanabol, Nicole M Saur, Terrah J Paul Olson","doi":"10.1016/j.ejso.2026.112353","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112353","url":null,"abstract":"<p><p>Total neoadjuvant therapy (TNT) has become a preferred approach for locally advanced rectal cancer (LARC), offering higher rates of complete response, the potential for organ preservation, and reduced distant metastasis. However, the trials establishing these benefits largely excluded older adults and patients with functional impairment, leaving limited guidance on who is fit enough to receive TNT. Improper selection of older patients for TNT poses dueling risks: exclusion of candidates based on chronological age allows for potential undertreatment while delivery of a prolonged, multimodal regimen to patients without adequate physiologic reserve raises concern for overtreatment. This review describes how TNT stresses older adults across systemic, social, functional, physical, and cognitive domains and how these domains should inform frailty assessment. We discuss available assessment approaches, including deficit accumulation indices (DAIs), point-of-care performance measures, chemotherapy toxicity prediction tools, and comprehensive geriatric assessment, and conclude that no single instrument is sufficient. Instead, frailty assessment in TNT candidates should be holistic and multi-domain, longitudinal, and involve several disciplines. We propose that frailty be treated as a modifiable baseline rather than an exclusion criterion, with potential for using the neoadjuvant interval for domain-targeted prehabilitation and as a dynamic stress test of physiologic reserve. Finally, we describe how frailty assessment can anchor shared decision-making, aligning treatment with the priorities of older adults, who frequently value quality of life, independence, and cognition over longevity. Individualized, frailty-informed decision-making can help ensure that the benefits of TNT reach appropriately selected older patients.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"52 12","pages":"112353"},"PeriodicalIF":3.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival differences between radiofrequency ablation and surgical resection for early hepatocellular carcinoma: a population-based comparative effectiveness study. 早期肝细胞癌射频消融与手术切除的生存差异:一项基于人群的比较疗效研究。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-05 DOI: 10.1016/j.ejso.2026.112361
Kehan Lin, Xiangting Ding, Xiaoju Li, Guangliang Huang, Baoxian Liu
{"title":"Survival differences between radiofrequency ablation and surgical resection for early hepatocellular carcinoma: a population-based comparative effectiveness study.","authors":"Kehan Lin, Xiangting Ding, Xiaoju Li, Guangliang Huang, Baoxian Liu","doi":"10.1016/j.ejso.2026.112361","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112361","url":null,"abstract":"<p><strong>Introduction: </strong>Radiofrequency ablation (RFA) is less invasive than resection for early hepatocellular carcinoma (HCC); randomized trials in small tumors have not demonstrated a significant overall survival difference between the two treatments, whereas observational comparisons have suggested longer survival after resection.</p><p><strong>Materials and methods: </strong>We analyzed data from 17 registries of the Surveillance, Epidemiology, and End Results (SEER) Program (2004-2023) for patients with T1N0M0 HCC ≤30 mm treated with RFA or resection. The primary effect measure was the restricted mean survival time difference (ΔRMST; RFA minus resection) at 24, 36, and 48 months.</p><p><strong>Results: </strong>Among 2763 patients (1287 resection; 1476 RFA), overlap-weighted ΔRMST was -0.58 (95% CI, -0.96 to -0.20), -1.88 (95% CI, -2.61 to -1.16), and -3.86 months (95% CI, -4.99 to -2.73) at 24, 36, and 48 months, respectively; corresponding adjusted overall survival differences were -8.2, -13.5, and -17.2 percentage points. In exploratory subgroup analyses, adjusted differences were smallest for tumors ≤20 mm and largest for tumors 31-50 mm.</p><p><strong>Conclusion: </strong>Resection was associated with longer restricted survival than RFA in localized T1N0M0 HCC ≤30 mm; larger negative adjusted estimates were observed at successively longer analysis horizons. The smallest adjusted differences were observed for tumors ≤20 mm, although uncertainty increased at longer follow-up; these estimates may inform treatment discussions but do not establish equivalence. In exploratory analyses of tumors >30 mm, adjusted survival differences were larger and consistently favored resection.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"53 1","pages":"112361"},"PeriodicalIF":3.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgery is still the gold standard for dMMR/MSI-H colon cancer. 手术仍然是dMMR/MSI-H结肠癌的金标准。
IF 3.5 2区 医学
Ejso Pub Date : 2026-11-05 DOI: 10.1016/j.ejso.2026.112347
Jérémie H Lefèvre, Romain Cohen, Yann Parc, Thierry André
{"title":"Surgery is still the gold standard for dMMR/MSI-H colon cancer.","authors":"Jérémie H Lefèvre, Romain Cohen, Yann Parc, Thierry André","doi":"10.1016/j.ejso.2026.112347","DOIUrl":"https://doi.org/10.1016/j.ejso.2026.112347","url":null,"abstract":"<p><p>Neoadjuvant immune checkpoint inhibitors (ICI) produce unprecedented pathological responses in localised dMMR/MSI-H colon cancer, and organ preservation is now proposed by analogy with dMMR rectal cancer. This analogy is misleading. Upfront colectomy is a short, safe procedure that cures most patients, since most are stage I-II. Segmental colectomy carries very low morbidity, 5-year overall survival exceeds 85%, and functional impairment or stoma-related issues are almost non-existent. Organ preservation requires around six months of ICI, exposes patients to immune-related toxicity and to obstruction or perforation of the primary tumour, relies on response assessment blind to nodal status, risks inappropriate treatment of a misdiagnosed MSI status, is expensive, and leaves an at-risk colon in Lynch syndrome. Partial colectomy should remain the standard - upfront for most patients, after neoadjuvant ICI for selected cases such as cT4 or tumours at risk of R1 resection - with organ preservation confined to randomised trials.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":" ","pages":"112347"},"PeriodicalIF":3.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书